Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $25 to $31.
August 09, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on PTC Therapeutics and raises the price target from $25 to $31.
The raised price target from $25 to $31 by Barclays suggests a positive outlook for PTC Therapeutics, which could lead to a short-term increase in stock price. However, the Equal-Weight rating indicates a neutral stance, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100